India Cut Cancer Drug Prices by Up to 96%. The Hard Part Comes Next.

On Monday, a cancer patient in India filling a prescription for palbociclib, a breast-cancer drug, began paying Rs 2,720 for a pack that cost Rs 40,421 last week. A vial of bevacizumab, used against lung and cervical cancer, fell from Rs 25,995 to Rs 3,318. A denosumab injection for bone metastases dropped from Rs 24,955 to Rs 6,240. Across 1,366 formulations of 121 anti-cancer medicines, the government says patients will save an estimated Rs 3,540 crore a year. The steepest cut was 96.45 per cent.
This is India’s largest intervention in cancer drug pricing. But the detail matters as much as the headline. The reform does not make all cancer drugs cheaper, and it leaves the most expensive patented medicines untouched. It also reveals where the next fight over affordable cancer care will be fought.
India has squeezed the pharmacy. The patent is still standing.
The Crescent World
What the government actually did
The National Pharmaceutical Pricing Authority capped the trade margin on 137 non-scheduled anti-cancer drugs at 30 per cent of the maximum retail price, using extraordinary powers under Paragraph 19 of the Drugs (Prices Control) Order, 2013. The gazette notification was issued on October 17; revised prices took effect on November 9. By then, 85 companies had reported new maximum retail prices for 1,366 stock-keeping units, covering 121 drugs.
The mechanism is important. India already fixes ceiling prices for scheduled essential medicines. Cancer drugs outside that list were governed only by the market — and the market had a peculiar structure. The trade margin, the difference between what a manufacturer charges a distributor and what a patient pays at the counter, could reach several times the procurement price. Capping the margin attacks the part of the chain that adds cost without adding medicine.
The results are uneven by design. Of the 1,366 formulations, 401 saw cuts of Rs 1,000 to Rs 5,000, 207 fell by Rs 5,000 to Rs 10,000, and 144 dropped by Rs 10,000 to Rs 20,000. Eight medicines fell by more than Rs 50,000 per unit. But 201 formulations had no change at all, and another 255 fell by less than Rs 100. In total, 456 medicines saw negligible movement.
The patent problem
The most uncomfortable finding is that the most expensive drugs barely moved. Only four of the 57 formulations priced above Rs 1 lakh per unit saw any reduction. Prices did not change for 62 formulations of 39 patented or single-source drugs — medicines marketed by only one company in India. Pembrolizumab, sold as Keytruda, remained at about Rs 2,16,500 for a 100 mg vial. Osimertinib, sold as Tagrisso, stayed at about Rs 4,16,492 for 30 tablets.
The reason is structural. Trade margin rationalisation squeezes the distribution layer. If a patented drug’s margin is already within 30 per cent of its retail price, there is nothing for the cap to bite on. The manufacturer’s price — protected by the patent — is the wall. No amount of pharmacy reform can bring down a number set by a legal monopoly.
That is why patient groups responded with a mixture of relief and frustration. Relief, because thousands of families will pay less for chemotherapy, supportive care and generic oncology medicines. Frustration, because the newer targeted therapies and immunotherapies — the drugs that transformed survival rates in richer countries — remain out of reach for most Indian households. The tools lie elsewhere in the law: compulsory licensing, government use, negotiated voluntary licences and domestic biosimilar manufacturing.
India has used compulsory licensing before. In 2012, it granted a licence to Natco Pharma to manufacture Bayer’s cancer drug Nexavar, a decision that lowered the price dramatically and survived years of litigation. That precedent still exists, but it has been used sparingly since. The political economy of invoking it against modern immunotherapy is far more complicated than it was against a single kidney-cancer pill.
What the Global South can borrow
Most low- and middle-income countries face the same split that India does: inexpensive generics for older drugs, unaffordable patented medicines for the newest ones. India’s experiment offers a template for the first half of that problem. A regulator can cap distribution margins, publish maximum retail prices, require hospitals to display them, and let patients check what they should pay. None of that requires a sophisticated patent bureaucracy. It requires political will and a pricing authority with teeth.
The second half is harder. For patented drugs, countries need collective bargaining, voluntary licensing, technology transfer and, where necessary, compulsory licensing. The model that worked for HIV — pooled procurement, generic competition and political pressure — has not been replicated for oncology, partly because cancer drugs are more complex to manufacture and partly because the market is smaller and more fragmented. India, with its scale and generic industry, is one of the few countries that could change that calculus.
There is also a manufacturing story. India supplies a large share of the world’s generic oncology medicines but imports most patented biologics. Building capacity for biosimilars — with the clinical trials, regulatory pathways and quality systems they require — would do more for long-run affordability than any single price cap. The government’s production-linked incentives have started that process, but the pipeline is long.
The reform is real, and it should not be dismissed because it is partial. For a patient on a generic chemotherapy regimen, a 50 per cent cut is the difference between finishing treatment and stopping halfway. But the headline number flatters the policy. The average cut is closer to Rs 6,000 per formulation, and the medicines that matter most to the richest and most desperate patients did not move.
India has shown that it can regulate the middle of the supply chain. The harder task is to regulate the monopoly at the top, through licensing, negotiation and local production. Making the pharmacy cheaper is a genuine victory. Making the patent cheaper is the unfinished one.
Illustration generated with AI (Z-Image Turbo, rendered locally) for The Crescent World.